Practical Approaches to the Management of Dual Refractory Multiple Myeloma
Hans C Lee1, Tomer M Mark2, Jatin J Shah3
1University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 429, Houston, TX, 77030, USA.
Abstract:
The outcome of myeloma patients' dual refractory to lenalidomide and bortezomib is generally poor and represents a significant clinical challenge with a clear need for new therapeutic approaches. This has prompted the development of next-generation proteasome inhibitors and immunodulatory drugs (IMiDs), as well as new classes of drugs with novel mechanisms of action. As a result, several of these agents have received regulatory approval that have shown promising activity in the dual refractory setting including the second-generation proteasome inhibitor carfilzomib and third-generation IMiD pomalidomide. Moreover, the regulatory approval of several first-in-class drugs for myeloma such as the histone deacetylase (HDAC) inhibitor panobinostat and the anti-CD38 monoclonal antibody daratumumab has further broadened the therapeutic landscape for these patients. Collectively, these advances have provided new treatment strategies in dual refractory myeloma as well as important insights for the development of future studies with rationally designed drug combinations to target this challenging patient population.
Insights
Treatment options for myeloma patients refractory to lenalidomide and bortezomib are limited. New therapies, including novel proteasome inhibitors and immunomodulatory drugs, offer improved outcomes for this challenging condition.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma patients refractory to lenalidomide and bortezomib face poor prognoses.
- There is a critical need for novel therapeutic strategies in dual-refractory myeloma.
- Advances in drug development have introduced new agents targeting myeloma.
Purpose of the Study:
- To review the current therapeutic landscape for dual-refractory multiple myeloma.
- To highlight the efficacy of newly approved agents in this patient population.
- To inform future research directions for combination therapies.
Main Methods:
- Review of recent clinical trials and regulatory approvals.
- Analysis of data on novel proteasome inhibitors and immunomodulatory drugs (IMiDs).
- Examination of first-in-class drugs like HDAC inhibitors and monoclonal antibodies.
Main Results:
- Second-generation proteasome inhibitor carfilzomib shows activity.
- Third-generation IMiD pomalidomide demonstrates efficacy.
- First-in-class agents such as panobinostat and daratumumab expand treatment options.
Conclusions:
- New therapeutic agents have improved outcomes for dual-refractory myeloma.
- These advances provide valuable insights for developing future combination studies.
- Rationally designed drug combinations are crucial for targeting this difficult-to-treat population.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:26Psychosis: Goals of Pharmacotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...